/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

HUMACYTE INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.3096 0.0238(2.38%) HUMA at 04 Dec 2025 04:34 PM Biotechnology
Lowest Today 1.235
Highest Today 1.31
Today’s Open 1.28
Prev. Close 1.26
52 Week High 6.77
52 Week Low 1.09
Day’s Range: Low 1.235 High 1.31
52-Week Range: Low 1.09 High 6.77
1 day return -
1 Week return -4.07
1 month return -11.6
3 month return -10.99
6 month return -50.57
1 year return -70.73
3 year return -60.27
5 year return -86.78
10 year return -

Institutional Holdings

BlackRock Inc 6.28

Vanguard Group Inc 4.42

State Street Corp 2.77

Vanguard Total Stock Mkt Idx Inv 2.38

CenterBook Partners LP 2.17

iShares Russell 2000 ETF 1.89

Geode Capital Management, LLC 1.86

Marshall Wace Asset Management Ltd 1.67

Millennium Management LLC 1.61

UBS Group AG 1.54

SPDR® S&P Biotech ETF 1.43

Woodline Partners LP 1.26

Two Sigma Investments LLC 0.97

Susquehanna International Group, LLP 0.89

Morgan Stanley - Brokerage Accounts 0.87

Vanguard Institutional Extnd Mkt Idx Tr 0.81

Fidelity Small Cap Index 0.79

Northern Trust Corp 0.66

Private Advisor Group, LLC 0.63

Charles Schwab Investment Management Inc 0.58

iShares Russell 2000 Value ETF 0.53

iShares Biotechnology ETF 0.47

LPL Financial Corp 0.46

MEDICAL BioHealth EUR Acc 0.45

GSA Capital Partners LLP 0.41

Goldman Sachs Group Inc 0.40

AQR Capital Management LLC 0.40

Citadel Advisors Llc 0.39

Fidelity Extended Market Index 0.39

Vanguard Russell 2000 ETF 0.38

Schwab US Small-Cap ETF™ 0.35

State St Russell Sm Cap® Indx SL Cl I 0.28

Vanguard Health Care ETF 0.24

Schwab Small Cap Index 0.20

NT R2000 Index Fund - NL 0.19

iShares Micro-Cap ETF 0.18

iShares Russell 2000 Growth ETF 0.17

NT R2000 Index Fund - DC - NL - 3 0.15

iShares Russell 2000 Small-Cap Idx Instl 0.14

Fidelity Total Market Index 0.13

Market Status

Strong Buy: 5

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 235.96 M

PB Ratio 70.1666

PE Ratio 0.0

Enterprise Value 263.15 M

Total Assets 137.87 M

Volume 3269793

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:6187000 6.2M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:-49000 -0.0M, FY20:null 0.0M, FY19:6187000 6.2M

Annual Net worth FY23:-89390000 -89.4M, FY22:64219000 64.2M, FY21:37536000 37.5M, FY20:-68726000 -68.7M, FY19:null 0.0M

Quarterly Revenue Q3/2025:753000 0.8M, Q2/2025:301000 0.3M, Q1/2025:517000 0.5M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:493000 0.5M, Q2/2025:-1772000 -1.8M, Q1/2025:-1462000 -1.5M, Q3/2024:null 0.0M, Q2/2024:-1823000 -1.8M

Quarterly Net worth Q3/2025:-17510000 -17.5M, Q2/2025:-37658000 -37.7M, Q1/2025:39139000 39.1M, Q3/2024:-39202000 -39.2M, Q2/2024:-56663000 -56.7M

Fund house & investment objective

Company Information Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Organisation Biotechnology

Employees 218

Industry Biotechnology

CEO Dr. Laura E. Niklason M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow